Search

Your search keyword '"Lookstein, Robert"' showing total 758 results
Start Over Author "Lookstein, Robert"
758 results on '"Lookstein, Robert"'

208. Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry

Author

Garcia, Mark J., primary, Lookstein, Robert, additional, Malhotra, Rahul, additional, Amin, Ali, additional, Blitz, Lawrence R., additional, Leung, Daniel A., additional, Simoni, Eugene J., additional, and Soukas, Peter A., additional

Published
2015
Full Text
View/download PDF

212. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease

Author

Patel, Manesh R., primary, Conte, Michael S., additional, Cutlip, Donald E., additional, Dib, Nabil, additional, Geraghty, Patrick, additional, Gray, William, additional, Hiatt, William R., additional, Ho, Mami, additional, Ikeda, Koji, additional, Ikeno, Fumiaki, additional, Jaff, Michael R., additional, Jones, W. Schuyler, additional, Kawahara, Masayuki, additional, Lookstein, Robert A., additional, Mehran, Roxana, additional, Misra, Sanjay, additional, Norgren, Lars, additional, Olin, Jeffrey W., additional, Povsic, Thomas J., additional, Rosenfield, Kenneth, additional, Rundback, John, additional, Shamoun, Fadi, additional, Tcheng, James, additional, Tsai, Thomas T., additional, Suzuki, Yuka, additional, Vranckx, Pascal, additional, Wiechmann, Bret N., additional, White, Christopher J., additional, Yokoi, Hiroyoshi, additional, and Krucoff, Mitchell W., additional

Published
2015
Full Text
View/download PDF

221. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Author

Gerhard-Herman, Marie D., Gornik, Heather L., Barrett, Coletta, Barshes, Neal R., Corriere, Matthew A., Drachman, Douglas E., Fleisher, Lee A., Fowkes, Francis Gerry R., Hamburg, Naomi M., Kinlay, Scott, Lookstein, Robert, Misra, Sanjay, Mureebe, Leila, Olin, Jeffrey, Patel, Rajan A. G., Regensteiner, Judith G., Schanzer, Andres, Shishehbor, Mehdi H., Stewart, Kerry J., and Treat-Jacobson, Diane

Published
2017
Full Text
View/download PDF

222. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Author

Gerhard-Herman, Marie D., Gornik, Heather L., Barrett, Coletta, Barshes, Neal R., Corriere, Matthew A., Drachman, Douglas E., Fleisher, Lee A., Fowkes, Francis Gerry R., Hamburg, Naomi M., Kinlay, Scott, Lookstein, Robert, Misra, Sanjay, Mureebe, Leila, Olin, Jeffrey W., Patel, Rajan A. G., Regensteiner, Judith G., Schanzer, Andres, Shishehbor, Mehdi H., Stewart, Kerry J., and Treat-Jacobson, Diane

Published
2017
Full Text
View/download PDF

230. PS30 The Implications of Increasing Tortuosity on EVAR Outcomes

Author

Sanati-Mehrizy, Paymon, primary, Tadros, Rami O., additional, Faries, Peter L., additional, Weissler, Elizabeth, additional, Lookstein, Robert, additional, Weaver, Marvin V., additional, Vouyouka, Ageliki, additional, Malik, Rajesh, additional, Ellozy, Sharif, additional, and Marin, Michael, additional

Published
2014
Full Text
View/download PDF

232. Fibromuscular Dysplasia: State of the Science and Critical Unanswered Questions

Author

Olin, Jeffrey W., primary, Gornik, Heather L., additional, Bacharach, J. Michael, additional, Biller, Jose, additional, Fine, Lawrence J., additional, Gray, Bruce H., additional, Gray, William A., additional, Gupta, Rishi, additional, Hamburg, Naomi M., additional, Katzen, Barry T., additional, Lookstein, Robert A., additional, Lumsden, Alan B., additional, Newburger, Jane W., additional, Rundek, Tatjana, additional, Sperati, C. John, additional, and Stanley, James C., additional

Published
2014
Full Text
View/download PDF

239. A 20-Year Experience With Endovascular Repair of Abdominal Aortic Aneurysms: A Record of the Development and Evolution of Techniques, Devices, and Strategies

Author

Tadros, Rami O., primary, Faries, Peter L., additional, Lowe, Hannah L., additional, Schrier, Rachel, additional, Lookstein, Robert A., additional, Kim, Sung yup P., additional, Kim, Jamie, additional, Vouyouka, Ageliki G., additional, Ellozy, Sharif H., additional, and Marin, Michael L., additional

Published
2013
Full Text
View/download PDF

240. Preoperative Inferior Mesenteric Artery Embolization before Endovascular Aneurysm Repair: Decreased Incidence of Type II Endoleak and Aneurysm Sac Enlargement with 24-month Follow-up

Author

Ward, Thomas J., primary, Cohen, Stuart, additional, Fischman, Aaron M., additional, Kim, Edward, additional, Nowakowski, Francis S., additional, Ellozy, Sharif H., additional, Faries, Peter L., additional, Marin, Michael L., additional, and Lookstein, Robert A., additional

Published
2013
Full Text
View/download PDF

241. Endovascular Treatment of Renal Artery Stenosis in the Post CORAL Era.

Author

O'Connor, Paul and Lookstein, Robert

Abstract

Atherosclerotic renal artery stenosis (RAS) is highly associated with hypertension and renal insufficiency. Determining causation and who may benefit from RAS treatment remains difficult. The role of endovascular management of atherosclerotic RAS was challenged by several recent randomized controlled trials (RCT) which failed to demonstrate benefit of stenting. In the largest RCT to date, the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study did not find benefit of revascularization compared to medical therapy alone. While such RCTs represent the highest level of evidence to date, the conclusions drawn from them should be interpreted with caution due to substantial flaws in study design, inclusion, and exclusion criteria. The current AHA/ACC recommendations for RAS management are supported by many level-II evidence cohort studies which consistently found benefit of revascularization in groups with the highest likelihood of clinically significant RAS. Further study of these patient groups are needed to define a clear role for endovascular therapy of renal artery stenosis. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

242. Transradial Approach for Noncoronary Interventions: A Single-Center Review of Safety and Feasibility in the First 1,500 Cases.

Author

Posham, Raghuram, Biederman, Derek M., Patel, Rahul S., Kim, Edward, Tabori, Nora E., Nowakowski, F. Scott, Lookstein, Robert A., and Fischman, Aaron M.

Abstract

Purpose: To review safety and feasibility in a single center using transradial access (TRA) for noncoronary interventions.Materials and Methods: Retrospective analysis was performed of 946 patients evaluated for 1,531 consecutive TRA procedures from April 2012 to July 2015. Exclusion criteria included sheath > 6 F, Barbeau D waveform, radial artery (RA) diameter < 2 mm on ultrasound, history of severe aortic tortuosity or RA occlusion, and dialysis. TRA was attempted in 936 patients (62% men; median age, 62.4 y) who underwent 1,512 consecutive procedures (chemoembolization [n = 485], yttrium-90 mapping [n = 391] and infusion [n = 293], renal/visceral intervention [n = 172], uterine artery embolization [n = 116], peripheral intervention [n = 43], endoleak repair [n = 10], and other [n = 2]). Patients were evaluated for complications during follow-up at ~30 days.Results: Technical success was 98.2% (1,485/1,512). Major complications (0.13%) included pseudoaneurysm (n = 1) and seizure (n = 1). Minor complications (2.38%) included hematoma/bleeding (n = 13), RA occlusion (n = 11), arm pain (n = 6), and RA spasm (n = 6). Univariate analysis demonstrated a lower rate of adverse events in African American patients (hazard ratio [HR], 0.25; 95% confidence interval [CI], 0.07-0.86; P = .027). Twenty-seven cases (1.8%) required crossover to transfemoral access (TFA). Crossover rates were higher in female patients (P = .0055), height < 1.7 m (P = .024), renal/visceral interventions (P = .0003), and endoleak interventions (P = .0357). Multivariate analysis demonstrated intervention type to be the only significant predictor of TFA crossover (renal/visceral [HR, 4.48; 95% CI, 1.84-10.9; P = .001]; endoleak repair [HR, 9.54; 95% CI, 1.09-83.8; P = .042]).Conclusions: TRA was safe and well tolerated in a heterogeneous patient population across a range of peripheral vascular interventions. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

250. IN.PACT AV Access Trial: Economic Evaluation of Drug-Coated Balloon Treatment for Dysfunctional Arteriovenous Fistulae Based on 12-Month Clinical Outcomes.

Author

Pietzsch, Jan B., Geisler, Benjamin P., Manda, Bharati, Misra, Sanjay, Lyden, Sean P., Pflederer, Timothy A., and Lookstein, Robert A.

Abstract

Purpose: To study, from a U.S. payer's perspective, the economic consequences of drug-coated balloon (DCB) versus standard percutaneous transluminal angioplasty (PTA) use for the treatment of stenotic lesions in dysfunctional hemodialysis arteriovenous fistulae.Materials and Methods: Cost differences between DCBs and PTA at year 1 and beyond were calculated via 2 methods. The first approach used the mean absolute number of trial-observed access circuit reinterventions through 12 months (0.65 ± 1.05 vs 1.05 ± 1.18 events per patient for DCBs and PTA, respectively) and projected treatment outcomes to 3 years. The second approach was based on the trial-observed access circuit primary patency rates at 12 months (53.8% vs 32.4%) and calculated the cost difference on the basis of previously published Medicare cost for patients who maintained or did not maintain primary patency. Assumptions regarding DCB device prices were tested in sensitivity analyses, and the numbers needed to treat were calculated.Results: Using the absolute number of access circuit reinterventions approach, the DCB strategy resulted in an estimated per-patient savings of $1,632 at 1 year and $4,263 at 3 years before considering the DCB device cost. The access circuit primary patency approach was associated with a per-patient cost savings of $2,152 at 1 year and $3,894 at 2.5 years of follow-up. At the theoretical DCB device reimbursement of $1,800, savings were $1,680 and $2,049 at 2.5 and 3 years, respectively. The one-year NNT of DCB compared to PTA was 2.48.Conclusions: Endovascular therapy for arteriovenous access stenosis with the IN.PACT AV DCB can be expected to be cost-saving if longer follow-up data confirm its clinical effectiveness. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results